MedTrace Logo

An Observational Study to Investigate Clinical Usefulness of OROS Hydromorphone in Korean Cancer Patients

NCT01273454 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 648

Last updated 2013-09-04

No results posted yet for this study

Summary

This study aims to collect clinical information and to examine the usefulness and safety of ORal Osmotic System Hydromorphone in Korean cancer patients. The decision to treat patients with drug is as per physician discretion and that doses are determined based upon approved labeling recommendations and physician discretion.

Conditions

Interventions

DRUG

OROS Hydromorphone

8,16, 32 mg once a day for 4 weeks

Sponsors & Collaborators

  • Janssen Korea, Ltd., Korea

    lead INDUSTRY

Principal Investigators

  • Janssen Korea, Ltd. Clinical Trial · Janssen Korea, Ltd.

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2009-12-31
Completion
2009-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01273454 on ClinicalTrials.gov